Beta
10757

Role of MEK1 and DIAPH3 Expression in Colorectal Carcinoma

Article

Last updated: 01 Jan 2025

Subjects

-

Tags

-

Abstract

Background: Colorectal carcinoma (CRC) is one of the serious causes of morbidity and mortality worldwide. It is characterized by activating mutations in genes encoding Receptor Tyrosine Kinases (RAS, RAF, MEK1 or MEK2) which act as driving oncogenes. DIAPH3 deficiency has been reported to enhance cancer cell motility, invasion and metastasis and also correlates with aggressive behaviour of cancer.
Aim: To study the overexpression of MEK1 and DIAPH3 in CRC patients and their prognostic significance.
Methods: We examined the immunohistochemical expression of MEK1 and DIAPH3 using tissue microarray technique in 150 CRC specimens divided into two groups. The mucinous group (MG) included specimens of 56 mucinous adenocarcinoma and 19 signet ring cell carcinoma, while the non-mucinous group (NMG) included 75 non-mucinous adenocarcinoma specimens for comparison.
Results: MEK1 and DIAPH3 were strongly expressed in >50% of the studied specimens. The positivity of MEK1 expression was significantly higher in NMG compared to MG (66.7% and 34.3%, respectively; p < 0.001). In all cases, the overexpression of MEK1 was significantly associated with peri-tumoral and intra-tumoral lymphocytic response (p=0.005 and 0.008, respectively). Furthermore, MEK1 overexpression showed statistically significant correlation with better OS (p=0.023) in the whole group of patients. The expression of DIAPH-3 did not differ significantly between NMG and MG (53.3% and 47.1%, respectively; p=0.456). There was strong relation between the overexpression of MEK1 and DIAPH3 (p < 0.001).
Conclusion: The results suggest a potential synergistic role of MEK1 and DIAPH3 overexpression and the development of CRC. Further large scale studies are warranted.

DOI

10.21608/resoncol.2018.4042.1059

Keywords

colorectal cancer, Mucinous adenocarcinoma, MEK1, DIAPH3, TMA

Authors

First Name

Abd AlRahman

Last Name

Foda

MiddleName

M.

Affiliation

Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt

Email

abdofoda2009@yahoo.com

City

Mansoura

Orcid

-

First Name

Mohamed

Last Name

Ahmed

MiddleName

A. H.

Affiliation

Pathology Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt , Department of Pathology, East Sussex Health Care Trust, United Kingdom

Email

mohamed.ahmed@surrey.ac.uk

City

Suez

Orcid

-

First Name

Hend

Last Name

Elkalla

MiddleName

M. H. R.

Affiliation

Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt

Email

dr.hend1113@gmail.com

City

Mansoura

Orcid

0000-0002-6124-7379

First Name

Eman

Last Name

El-Zahaf

MiddleName

-

Affiliation

Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt

Email

eman_elzahaf@yahoo.com

City

Mansoura

Orcid

-

First Name

Heba

Last Name

Abdallah

MiddleName

-

Affiliation

Medical Oncology, Mit Ghamr Cancer Centre, Mit Ghamr, Egypt

Email

hebaoncology@gmail.com

City

-

Orcid

-

First Name

Heba

Last Name

Wagih

MiddleName

M.

Affiliation

Pathology Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

Email

hrwagih@yahoo.com

City

-

Orcid

-

First Name

Manal

Last Name

Sami

MiddleName

M.

Affiliation

Pathology Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

Email

manalsamighani@yahoo.com

City

-

Orcid

-

Volume

14

Article Issue

2

Related Issue

3808

Issue Date

2018-12-01

Receive Date

2018-06-10

Publish Date

2018-12-01

Page Start

75

Page End

82

Print ISSN

2357-0687

Online ISSN

2357-0695

Link

https://resoncol.journals.ekb.eg/article_10757.html

Detail API

https://resoncol.journals.ekb.eg/service?article_code=10757

Order

6

Type

Original Article

Type Code

200

Publication Type

Journal

Publication Title

Research in Oncology

Publication Link

https://resoncol.journals.ekb.eg/

MainTitle

Role of MEK1 and DIAPH3 Expression in Colorectal Carcinoma

Details

Type

Article

Created At

22 Jan 2023